Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Quantifying ethical tradeoffs for vaccine efficacy trials during severe epidemics

View ORCID ProfileSteven E. Bellan, View ORCID ProfileJuliet R.C. Pulliam, View ORCID ProfileRieke van der Graaf, View ORCID ProfileSpencer J. Fox, View ORCID ProfileJonathan Dushoff, View ORCID ProfileLauren Ancel Meyers
doi: https://doi.org/10.1101/193649
Steven E. Bellan
Department of Epidemiology and Biostatistics, University of Georgia, Athens, Georgia, United States of AmericaCenter for Ecology of Infectious Diseases, University of Georgia, Athens, Georgia, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Steven E. Bellan
  • For correspondence: steve.bellan@uga.edu
Juliet R.C. Pulliam
South African DST-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South AfricaDepartment of Biology and Emerging Pathogens Institute, University of Florida, Gainesville, Florida, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Juliet R.C. Pulliam
Rieke van der Graaf
University Medical Center Utrecht, Utrecht, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rieke van der Graaf
Spencer J. Fox
Department of Integrative Biology, The University of Texas at Austin, Austin, Texas, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Spencer J. Fox
Jonathan Dushoff
Department of Biology, McMaster University, Hamilton, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jonathan Dushoff
Lauren Ancel Meyers
Department of Integrative Biology, The University of Texas at Austin, Austin, Texas, United States of AmericaThe Santa Fe Institute, Santa Fe, New Mexico, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lauren Ancel Meyers
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Abstract

Background During emerging epidemics of highly fatal diseases, rapid development and testing of new vaccines may be critical to curbing transmission and saving lives. However, the design of vaccine efficacy trials in such contexts may face considerable logistical, epidemiological, or ethical impediments. Three different vaccine efficacy trials were conducted during the 2014-2016 Ebola virus epidemic in West Africa, each with different designs. At the time, there was vigorous debate on the tradeoff between a trial’s ability to yield information of scientific and societal value versus the perceived ethical dilemma of withholding potentially life-saving vaccines from control participants. Whereas the scientific value of a trial is often estimated in terms of statistical power, speed, and rigor, we lack similar metrics for the ethical costs of withholding interventions.

Methods and Findings Here, we introduce a conceptual framework that fills this gap and allows quantitative assessment of both the scientific value of a study and the risks incurred by trial participants. We show that even untested vaccines against severe diseases may be probabilistically beneficial—i.e. after accounting for realistic uncertainty in their safety and efficacy, trial participants are expected to be better off vaccinated than not. While accounting for this uncertainty, we estimate trial participant risk under a hypothetical, idealized vaccine rollout scenario and compare it to risk under various candidate trial designs, in order to elucidate specific quantitative tradeoffs between cumulative risk to trial participants and information gained. Through an illustrative simulation example, we highlight specific trial-design modifications that allow for conscientious balance between minimizing participant risk and acquiring information of societal value. These include modifications that affect the speed with which a trial would detect an efficacious vaccine (greater sample size or enrollment rate, interim analyses, or risk-prioritized vaccine rollout), which leads to earlier vaccination of control participants should the vaccine be efficacious, and those that systematically limit the risk “spent” by unvaccinated individuals (e.g., providing vaccination to controls after a delay, or presumptive vaccination of subjects above a risk threshold).

Conclusion We advocate this conceptual approach as a means of clarifying the tensions between opposing viewpoints and facilitating transparent discussion to aid ethical and efficient responses to future emerging epidemics.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted September 28, 2017.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Quantifying ethical tradeoffs for vaccine efficacy trials during severe epidemics
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
Share
Quantifying ethical tradeoffs for vaccine efficacy trials during severe epidemics
Steven E. Bellan, Juliet R.C. Pulliam, Rieke van der Graaf, Spencer J. Fox, Jonathan Dushoff, Lauren Ancel Meyers
bioRxiv 193649; doi: https://doi.org/10.1101/193649
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Quantifying ethical tradeoffs for vaccine efficacy trials during severe epidemics
Steven E. Bellan, Juliet R.C. Pulliam, Rieke van der Graaf, Spencer J. Fox, Jonathan Dushoff, Lauren Ancel Meyers
bioRxiv 193649; doi: https://doi.org/10.1101/193649

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Animal Behavior and Cognition (1524)
  • Biochemistry (2478)
  • Bioengineering (1731)
  • Bioinformatics (9662)
  • Biophysics (3895)
  • Cancer Biology (2968)
  • Cell Biology (4188)
  • Clinical Trials (135)
  • Developmental Biology (2624)
  • Ecology (4097)
  • Epidemiology (2031)
  • Evolutionary Biology (6892)
  • Genetics (5204)
  • Genomics (6495)
  • Immunology (2182)
  • Microbiology (6936)
  • Molecular Biology (2751)
  • Neuroscience (17258)
  • Paleontology (126)
  • Pathology (425)
  • Pharmacology and Toxicology (705)
  • Physiology (1056)
  • Plant Biology (2487)
  • Scientific Communication and Education (643)
  • Synthetic Biology (831)
  • Systems Biology (2687)
  • Zoology (429)